HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer
Some breast cancer patients may show ER, PR, or HER2 status conversion after NAT. Residual lesions need to be immunohistochemically re-tested to reassess the patient's receptor expression status and to adjust the subsequent treatment regimen.
Authors
- Jing Wang (ORCID: https://orcid.org/0000-0002-2735-7283)
- Mingxi Tang (ORCID: https://orcid.org/0000-0003-0715-9631)
- Xiuli Xiao
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Ya'an Polytechnic College (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fonc.2025.1522460
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87